This article was originally published in Pharmaceutical Approvals Monthly
Interim data from the first 51 of 120 prostate cancer patients to complete a pivotal Phase III trial of 30-day sustained release leuprolide acetate showed that it was "effective in reducing testosterone well below castrate levels with a corresponding positive response in [serum prostate specific antigen] values," according to a study abstract. Atrix plans to file an NDA for treatment of advanced prostate cancer during the first half of 2001. Atrix is enrolling patients for a trial of 90-day Leuprogel, and will follow that study with a trial of a 120-day formulation, the company sai
You may also be interested in...
No device-related warning letters were released by the US FDA the week of 22 September.
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.
Following Perrigo’s announcement of a recall of its generic albuterol inhalers in the US, the FDA has commented on the move and has revealed that thousands of complaints have been received over the clogging problem.